乳腺癌家族登记处高危女性乳腺肿瘤中的DNA甲基化
DNA Methylation in Breast Tumor from High-risk Women in the Breast Cancer Family Registry.
作者信息
Wu Hui-Chen, Southey Melissa C, Hibshoosh Hanina, Santella Regina M, Terry Mary Beth
机构信息
Department of Environmental Health Sciences, Mailman School of Public Health of Columbia University, New York, NY, U.S.A.
Department of Pathology, The University of Melbourne, Melbourne, Victoria, Australia.
出版信息
Anticancer Res. 2017 Feb;37(2):659-664. doi: 10.21873/anticanres.11361.
To examine DNA methylation profiles in breast tumors of women with a strong breast cancer family history, we measured methylation by bisulfite sequencing in 40 genes in 40 breast tumor tissues from women in the Breast Cancer Family Registry. We selected candidate genes from analysis of the Cancer Genome Atlas project (TCGA) breast data. Compared to TCGA breast cancer, BCFR cases are younger and more likely to be ER-negative. Overall, we found that many of the methylation differences between BCFR tumor and normal adjacent tissues were smaller than that in TCGA samples. We found only 32% of tested genes were hypermethylated in BCFR; the largest difference was 36.1% for SEPW1, and the smallest difference was 10% for RYR2. These data suggest the importance of examining breast cancer cases including familial cases enriched with early-onset cancers to identify methylation markers that can be examined in blood as biomarkers for early detection.
为了研究具有强烈乳腺癌家族史的女性乳腺肿瘤中的DNA甲基化谱，我们通过亚硫酸氢盐测序法对乳腺癌家族登记处女性的40个乳腺肿瘤组织中的40个基因进行了甲基化检测。我们从癌症基因组图谱计划（TCGA）乳腺数据的分析中选择了候选基因。与TCGA乳腺癌相比，BCFR病例更年轻，且更可能为雌激素受体（ER）阴性。总体而言，我们发现BCFR肿瘤与其相邻正常组织之间的许多甲基化差异小于TCGA样本中的差异。我们发现，在BCFR中，仅32%的检测基因发生了高甲基化；其中，SEPW1的最大差异为36.1%，RYR2的最小差异为10%。这些数据表明，检查包括富含早发性癌症的家族性病例在内的乳腺癌病例对于识别可在血液中检测的甲基化标志物作为早期检测的生物标志物具有重要意义。
Zotero 插件